{"id":24396,"date":"2023-09-08T06:37:28","date_gmt":"2023-09-08T10:37:28","guid":{"rendered":"https:\/\/platohealth.ai\/alveofit-receives-fda-approval-for-portable-digital-spirometer\/"},"modified":"2023-09-09T10:47:09","modified_gmt":"2023-09-09T14:47:09","slug":"alveofit-receives-fda-approval-for-portable-digital-spirometer","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/alveofit-receives-fda-approval-for-portable-digital-spirometer\/","title":{"rendered":"alveofit receives FDA approval for portable digital spirometer","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

<!–<\/p>\n

\n

–> <\/p>\n

\n
alveoair provides real-time insights to healthcare professionals and enables timely interventions in respiratory care. Credit: alveofit\/PRNewswire.<\/figcaption><\/figure>\n<\/p><\/div>\n

alveofit (Roundworks Technologies) has received approval from the US Food and Drug Administration (FDA)<\/a> for its portable digital spirometer, alveoair.<\/p>\n

With this approval, the company plans to start distributing the product in the US.<\/p>\n

Earlier this year, alveofit launched its office in New York to cater to the growing US market.<\/p>\n

It also claims that, along with the FDA approval, an alliance with AstraZeneca will expand its international business, particularly in the US and emerging economies.<\/p>\n

The product is part of alveofit\u2019s ecosystem, which provides real-time insights to healthcare professionals and enables timely interventions in respiratory care.<\/p>\n

These insights can offer predictive analytics along with AI models into respiratory health and allow clinicians to prioritise cases and deliver quality care.<\/p>\n

The CDSCO-certified alveoair is claimed to be India\u2019s first US FDA-cleared spirometer and is adopted by more than 400 healthcare facilities across India.<\/p>\n

In India, alveofit partnered with various companies, including NASSCOM COE, Forge Innovation & Ventures, PATH, DST and the India Sweden Innovation Centre.<\/p>\n

NASSCOM COE CEO Sanjeev Malhotra said: \u201cIt is good to see the product mature over the last couple of years and gain acceptance among the providers.<\/p>\n

\u201cI congratulate and wish alveofit a global success with recent approval from the FDA, making a difference in the lives of people in India and the world over.\u201d<\/p>\n

Furthermore, alveofit collaborated with AIIMS Delhi for clinical research and formed an alliance with Tatvacare to extend digital respiratory care solutions to the homes of patients.<\/p>\n

Share this article<\/span> <\/div>\n